MAIA Biotechnology, Inc. (MAIA) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, with its lead asset being ateganosine (THIO), a telomere-targeting agent. The company operates as a single segment focused on oncology drug development. As of August 11, 2025, there were 32,993,220 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5,346,963) | $(9,864,222) | $(16,946,731) |
| Net Loss Per Share (Basic/Diluted) | $(0.18) | $(0.34) | $(0.85) |
| Operating Expenses | $5,166,058 | $10,591,489 | $7,764,138 |
| Cash and Cash Equivalents (End of Period) | $10,144,522 | $10,144,522 | $11,579,391 |
| Working Capital | $5,999,102 | $5,999,102 | N/A |
| Accumulated Deficit | $(97,099,055) | $(97,099,055) | $(80,926,908) |
| Warrant Liability | $2,125,218 | $2,125,218 | $5,346,638 |
Material Changes vs. Prior Period
- Net Loss Improvement: The net loss for the six months ended June 30, 2025, decreased by approximately 42% compared to the same period in 2024. This improvement was primarily driven by a $9.9 million gain from the change in fair value of warrant liabilities, contrasting with a $9.3 million loss in the prior year.
- Operating Expenses: Total operating expenses increased by 36% year-over-year to $10.6 million. Research and Development (R&D) expenses rose 44% to $6.3 million due to increased clinical and scientific research costs. General and Administrative (G&A) expenses increased 26% to $4.3 million, driven by higher professional fees and stock-based compensation.
- Capital Raising: The company raised approximately $5.9 million through four private placement rounds and $3.0 million via its At-The-Market (ATM) offering during the first half of 2025. This contrasts with $5.3 million from private placements and $7.9 million from ATM in the prior year.
- Warrant Liability: The warrant liability decreased from $2.7 million at year-end 2024 to $2.1 million at June 30, 2025, resulting in a non-cash gain of $565,387 for the six-month period.
Outlook, Management Commentary, and Risks
- Clinical Progress:
- THIO-101 (NSCLC): Updated data showed a median overall survival of 17.8 months for third-line patients. A new partial response was identified after 20 months of treatment. The trial is expanding to include a monotherapy arm and enrollment in Taiwan.
- THIO-104 (Phase 3): The company plans to initiate a pivotal Phase 3 trial in 2025 for third-line NSCLC patients, aiming for a filing for early full commercial approval in 2026.
- Partnerships: New clinical supply agreements were signed with Roche (atezolizumab) and BeOne Medicines (tislelizumab) for trials in HCC, SCLC, and CRC. An agreement with Regeneron continues for NSCLC trials.
- Regulatory: The FDA granted Fast Track designation for ateganosine for NSCLC in July 2025.
- Liquidity and Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year following the report date. While cash reserves are approximately $10.1 million, the company has no revenue and expects to continue incurring losses. Additional equity or debt financing will be required to fund operations and clinical trials.
- Risks: Key risks include the failure to secure additional funding, the uncertainty of clinical trial outcomes, and the potential for dilution from future equity issuances. The company also faces risks related to the wars in Ukraine and Israel, though it has terminated planned research in impacted areas.
Investor Verification Checklist
- Cash Runway: Verify the specific monthly burn rate and the timeline for the next anticipated financing event given the "substantial doubt" disclosure.
- Dilution Impact: Review the terms of the recent private placements and ATM offerings, noting the issuance of warrants with exercise prices ranging from $1.50 to $2.05, which may lead to significant future dilution.
- Clinical Milestones: Confirm the enrollment status and data readout dates for the THIO-101 expansion and the planned initiation of the THIO-104 Phase 3 trial.
- Warrant Liability Volatility: Monitor the fair value of the remaining warrant liability ($2.1 million), as fluctuations in the stock price will continue to impact reported net income/loss significantly.
- Related Party Transactions: Note the participation of directors and a >5% shareholder (FGMK) in recent private placements and the issuance of stock for services.